Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Mar;14(1):67-80.
doi: 10.1111/vco.12068. Epub 2013 Oct 24.

Evaluation of adjuvant carboplatin chemotherapy in the management of surgically excised anal sac apocrine gland adenocarcinoma in dogs

R M Wouda  1 , J Borrego  1   2   3 , N S Keuler  4 , T Stein  1
Affiliations

Evaluation of adjuvant carboplatin chemotherapy in the management of surgically excised anal sac apocrine gland adenocarcinoma in dogs

R M Wouda et al. Vet Comp Oncol. 2016 Mar.

Abstract

There is no widely accepted standard of care for canine anal sac apocrine gland adenocarcinoma (ASAGAC). Surgery alone is inadequate in many cases, but the benefit of adjuvant chemotherapy is not well established. The primary objective of this retrospective study was to evaluate the role of carboplatin chemotherapy in the post-operative management of ASAGAC. Seventy-four dogs with naturally occurring ASAGAC underwent surgery. Forty-four dogs received adjuvant carboplatin and 30 did not. Median overall survival (OS) was 703 days. Median time to progression (TTP) was 384 days. Only primary tumour size and lymph node metastasis at diagnosis significantly impacted the outcome. Differences in OS and TTP, between the dogs that received adjuvant carboplatin and those that did not, failed to reach statistical significance. Treatment of progressive disease, whilst not limited to chemotherapy, significantly prolonged the survival. This study shows that adjuvant carboplatin chemotherapy is well tolerated and may have a role in the management of dogs with ASAGAC.

Keywords: canine; carboplatin; outcome; surgery.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest

The authors declare no conflicts of interest.

Figures

Figure 1.
Figure 1.
Estimated Kaplan-Meier survival curve for overall survival times in 74 dogs with ASAGAC treated with surgery +/−adjuvant carboplatin chemotherapy.
Figure 2.
Figure 2.
Estimated Kaplan-Meier survival curve for time to progression in 74 dogs with ASAGAC treated with surgery +/− adjuvant carboplatin chemotherapy.
Figure 3.
Figure 3.
Estimated Kaplan-Meier survival curves for overall survival times in dogs with ASAGAC diagnosed with (red) or without (black) metastasis at the time of initial diagnosis. The median overall survival time of 448 days in dogs with metastasis at the time of initial diagnosis was significantly shorter (P= 0.042) than the 761-day median overall survival time in dogs that did not have metastasis.
Figure 4.
Figure 4.
Estimated Kaplan-Meier survival curves for time to progression in dogs with ASAGAC, with (red) or without (black) metastasis at the time of initial diagnosis. The median time to progression of 134 days in dogs with metastasis at the time of initial diagnosis was significantly shorter (P= 0.018) than the 448-day median time to progression in dogs that did not have metastasis at the time of initial diagnosis.
Figure 5.
Figure 5.
Estimated Kaplan-Meier survival curves for overall survival times in dogs with ASAGAC, with or without metastasis at the time of initial diagnosis, and that did or did not receive adjuvant carboplatin chemotherapy. Dogs that did not have metastasis at the time of diagnosis and received adjuvant carboplatin chemotherapy (green) had the longest median survival time of 952 days, whilst dogs that did have metastasis at the time of initial diagnosis and did not receive adjuvant carboplatin chemotherapy (red) had the shortest median survival time of 448 days.
Figure 6.
Figure 6.
Estimated Kaplan-Meier survival curves for time to progression in dogs with ASAGAC, with or without metastasis at the time of initial diagnosis, and that did or did not receive adjuvant carboplatin chemotherapy. Dogs that did not have metastasis at the time of diagnosis and received adjuvant carboplatin chemotherapy (green) had the longest median time to progression of 745 days, whilst dogs that did have metastasis at the time of initial diagnosis and did receive adjuvant carboplatin chemotherapy (blue) had the shortest median time to progression of 113 days.
See this image and copyright information in PMC

References

    1. Berrocal A, Vos JH, van den Ingh TS, Molenbeek RF and van Sluijs FJ. Canine perineal tumors, Journal of Veterinary Medicine Series A 1989; 36: 739–749. - PubMed
    1. Goldschmidt MH and Hendrick MJ. Anal sac gland carcinoma In: Meuten DJ, ed. Tumors in Domestic Animals, 4th ed. Ames, Iowa: Iowa State Press; 2002: 74–76.
    1. Goldschmidt MH and Zoltowski C. Anal sac adenocarcinoma in the dog: 14 cases. The Journal of Small Animal Practice 1981; 22: 119–128. - PubMed
    1. Ross JT, Scavelli TD, Matthieson DT and Patnaik AK. Adenocarcinoma of the apocrine glands of the anal sac in dogs: a review of 32 cases. Journal of the American Animal Hospital Association 1991; 27: 349–355.
    1. Bennett PF, DeNicola DB, Bonney P, Glickman NW and Knapp DW. Canine anal sac adenocarcinomas: clinical presentation and response to therapy. Journal of Veterinary Internal Medicine 2002; 16: 100–104. - PubMed

Publication types

LinkOut - more resources